CHD — Church & Dwight Co., Inc.

Sentiment is genuinely split. The positive side: Q2 2026 (reported 2026-07-31) net sales of $1.53B beat the $1.50B consensus, organic sales grew 5.8% versus 3% guidance, management raised FY26 organic growth to 4–5% and FY26 adjusted EPS to $3.74–$3.81, and the company paid its 502nd consecutive quarterly dividend on 2026-09-01. The negative side: adjusted EPS of $0.89 was in line-to-slightly-below aggressive whisper numbers, and the tape has punished the name anyway — as of 2026-09-13 the stock was down 4.46% in a week and 7.0% in a month, with RSI at 32.11 and price below the 20-, 50- and 200-day averages. Analysts sit at a Hold-to-cautious-Buy consensus with price targets clustered at $104–$106 (Wells Fargo $110, JPM $105), while 13F filings show institutional accumulation offset by periodic insider sales. Net: a well-liked defensive name that the market is no longer willing to pay a premium multiple for without clearer margin conversion.

The reported headline trend looks sluggish but the underlying trend is improving. Reported revenue: Q3'23 $1.456B, Q3'24 $1.511B, Q4'24 $1.582B, Q1'25 $1.467B, Q2'25 $1.506B, Q3'25 $1.586B, Q4'25 $1.644B, Q1'26 $1.469B, Q2'26 $1.530B — Q2'26 was up only 1.6% YoY, and Q1'26 was up just 0.15% YoY, yet Q2'26 organic sales rose 5.8%. That gap is the single most important thing in the numbers: reported growth is being masked by roughly 4 points of FX/portfolio drag, so the surface-level 'low single digit' read understates real demand momentum. Gross margin is genuinely expanding: Q2'26 gross margin 45.35% vs 42.95% in Q2'25 (+2.4pt), and Q1'26 46.38% vs 44.96% (+1.4pt). Operating margin, however, is not following through — 18.07% in Q2'26 vs 17.37% in Q2'25 (+0.7pt) but 19.81% in Q1'26 vs 20.13% in Q1'25 (−0.3pt), implying the gross-margin gains are being reinvested (marketing, digital, M&A integration) rather than dropping to the bottom line. Free cash flow is the cleanest signal of health: TTM FCF of $1,115M ($256.9M + $142.9M + $308.2M + $407.3M) versus $930.6M in the prior TTM window, up roughly 20% YoY, with the accruals ratio at −0.92% (cash generation running ahead of reported net income — a good sign). One clear distortion to flag: Q3 2024 printed an operating loss of −$91.5M and a net loss of −$75.1M (−$0.31 EPS), an obvious one-off charge quarter that is not evidence of structural deterioration and drags down any multi-year trend line. Verdict: stable-to-inflecting. The inflection is real and management has confirmed it by raising guidance, but it is not yet visible in reported revenue or operating margin.

Mixed, and the split matters. On relative-to-itself: as of 2026-09-13 at $94.15, CHD's 30.2x trailing P/E and 3.58x P/S are both below the company's 5-year averages of 35.95x and 3.99x — the deterministic score's 'Cheap vs. its own history' label is fair. On absolute terms it is not cheap: 24.9x forward earnings (using the $3.78 next-FY consensus EPS) and 20.2x EV/EBITDA for a business growing reported revenue in the low single digits is a full multiple, and P/B of 5.13 with a price/cash flow of 88.0 is rich. The PEG of 0.659 looks attractive but flatters the name because the forward EPS estimate sits on a depressed prior-year base. The honest read: this is a quality staple priced roughly at fair value to a small premium — you are paying about 25x forward for 4–5% organic growth and a 1.2% dividend yield (though a ~5.0% trailing FCF yield on $1.115B TTM FCF is more supportive). Cheap versus where it used to trade; not cheap versus what it does.

The market is pricing CHD as a stable compounder, not a turnaround — roughly 25x forward for mid-single-digit organic growth — so the burden of proof is on margin conversion, not the top line. The tell is that a quarter that beat on organic sales and raised full-year guidance was rewarded with a 7% one-month decline into 2026-09-13: investors believe the demand story and are skeptical about the earnings bridge. Watch two things. First, whether the +2.4pt Q2 gross-margin expansion finally flows into operating margin (stuck at ~17–20% for four quarters) — if it does, the $3.74–$3.81 FY26 adjusted EPS guide becomes beatable, and today's multiple looks defensible. Second, whether reported revenue (up only 1.6% YoY in Q2'26 versus +5.8% organic) closes the gap with organic as FX and portfolio drag fade — that is the mechanical catalyst that would re-rate the stock. If organic instead decelerates back toward 3% while operating margin stays flat, there is no earnings cushion at 25x forward to absorb it.

As of 2026-09-13, the technical picture is weak, not yet washed out. RSI(14) stood at 32.11 — close to, but not through, the 30 oversold line. Price at $94.15 was 4.93% below the 20-day SMA (~$99.0), 4.94% below the 50-day SMA (~$99.0, effectively converged with the 20-day), and 1.06% below the 200-day SMA (~$95.2). Forward returns were negative across every window: −4.46% (1 week), −7.00% (1 month), −3.50% (3 months), −3.68% (6 months). Translation: a short-term downtrend inside a longer sideways range (52-week band $81.33–$106.04) with momentum still pointed down. Entry-timing implication: this is a scale-in setup, not a falling-knife catch — RSI nearing 30 with price only ~1% under the 200-day is mean-reversion-friendly, but the confirmation signal to wait for is a reclaim of the ~$99 20/50-day cluster, which would also mark the point where the recent drawdown stops being a downtrend.

• Defensive sector rotation: rising geopolitical tension (Strait of Hormuz headlines), surging oil, and a renewed bond selloff have pushed institutional money into consumer staples; CHD's 0.471 beta makes it a textbook low-volatility haven, which is a genuine tailwind to the multiple.
• Higher long-end yields: a 30.2x trailing P/E is a long-duration asset, and a renewed 10-year Treasury selloff raises the discount rate applied to stable staple cash flows, capping multiple expansion even as fundamentals improve.
• FX and input-cost volatility: the ~4pt gap between reported revenue growth (+1.6% in Q2'26) and organic (+5.8%) is largely currency/portfolio related, and localized input volatility plus commodity swings remain live swing factors for gross margin.
• Promotional and private-label intensity: household products remain a competitive, promotion-heavy category where retailer brands press on price — CHD's value-oriented portfolio (ARM & HAMMER, baking soda, value detergents) is a relative advantage but not immunity.
• Tariff/trade policy exposure: imported components and international operations mean trade-policy shifts can hit landed costs and currency translation, adding noise to an already thin reported-growth number.

• Q3 2026 earnings on 2026-10-30 — the first real test of whether the raised 4–5% FY26 organic guidance holds through back-to-school and early holiday takeaway, and whether gross-margin gains finally convert into operating margin.
• Delivery against the raised FY26 adjusted EPS range of $3.74–$3.81 and any further upward revision at the Q3 print.
• Analyst target revisions following the guide raise (Wells Fargo to $110 on 2026-07-08, J.P. Morgan to $105 on 2026-07-16) — broader follow-through would help reverse the current negative price momentum.
• Continued bolt-on M&A integration and international scaling (Touchland, Hero, TheraBreath), which are the stated growth pillars and a potential source of upside to organic growth.
• Another annual dividend increase — the 502nd consecutive quarterly dividend was paid 2026-09-01, and extending the streak reinforces the income/defensive bid.

• Valuation risk is the biggest one: 24.9x forward earnings and 20.2x EV/EBITDA leave almost no cushion for a miss, and the PEG of 0.659 is flattered by a depressed prior-year earnings base rather than genuine acceleration.
• Low reported revenue growth: +1.6% YoY in Q2'26 and +0.15% in Q1'26, with the organic/reported gap dependent on FX and portfolio moves that CHD does not control.
• Margin conversion failure: gross margin expanded ~2.4pt YoY in Q2'26, but operating margin has been stuck at roughly 17–20% for four straight quarters — if reinvestment keeps absorbing the gains, the EPS guide gets harder to hit.
• Organic growth deceleration: the 5.8% Q2'26 print is well above the long-run trend; a return toward the 3% prior guidance would quickly expose the premium multiple.
• Competitive and consumer pressure: promotional intensity, private-label trade-down, and elasticities remain the items management itself says it is monitoring.
• Rate sensitivity and momentum: a sustained rise in long yields plus the existing downtrend (down 7.0% in the month to 2026-09-13, below all major moving averages) can keep pressure on the stock even if results are fine, and insider sales have offset institutional accumulation in recent filings.

Church & Dwight is a genuinely good, low-beta staples business — 45.6% gross margin, 12% net margin, 18.4% ROE, ~$1.1B of TTM free cash flow and cash generation running ahead of reported earnings — and it is trading below its own 5-year average multiple (30.2x trailing vs 35.95x average) at a time when organic growth just accelerated to 5.8% and management raised guidance. But at ~24.9x forward earnings for 4–5% organic growth, with reported revenue up only 1.6%, operating margin flat at ~18%, and the stock in a clear short-term downtrend (RSI 32.1, below all major moving averages as of 2026-09-13), you are paying a full price for a story that has only partly shown up in the financials. This is a hold-and-accumulate-on-weakness name for a defensive income sleeve, not a compelling fresh buy at $94.15 — the interesting entry would be closer to the 200-day support or after evidence that gross-margin gains are reaching operating profit.

Primary method: a justified forward P/E of 26.0x applied to the next-FY consensus EPS of $3.78 (which matches the midpoint of management's own raised FY26 adjusted guidance of $3.74–$3.81), giving $98.28 — a modest premium to staples peers justified by CHD's 45.6% gross margin, 18.4% ROE, low 0.471 beta, ~5.0% trailing FCF yield on $1.115B TTM free cash flow, and 502-quarter dividend record. Cross-check via EV/EBITDA: ~19.0x forward EBITDA of roughly $1.27B yields an EV of ~$24.1B; subtracting ~$1.95B of net debt ($2.206B long-term debt less $0.255B cash) and dividing by ~236.9M shares gives ~$93.60. Weighting the two (0.6 P/E, 0.4 EV/EBITDA) lands at approximately $96.40, rounded to $97.00, which implies about 3% upside from the 2026-09-13 price of $94.15 — consistent with a Neutral lean rather than a screaming value.